Boehringer Ingelheim Entered into a Collaboration and License Agreement with Surrozen to Develop SZN-413 for the Treatment of Retinal Diseases
Shots:
- Surrozen to receive $12.5M up front & ~$586.5M in success-based development, regulatory & commercial milestones along with royalties
- Boehringer Ingelheim to get an exclusive license globally to develop SZN-413 & other Fzd4-specific Wnt-modulating molecules for all purposes & retinal diseases along with lead development & commercial responsibilities
- The collaboration combines Surrozen’s SWAP technology for modulating Wnt signaling with Boehringer Ingelheim’s R&D expertise to develop a treatment for eye disease patients. In preclinical models, SZN-413 stimulated Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage
Ref: Globenewswire | Image: Boehringer Ingelheim
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
